Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

Mattia D’Agostino; Alessandra Larocca; Massimo Offidani; Anna Marina Liberati; Gianluca Gaidano; Maria Teresa Petrucci; Daniele Derudas; Andrea Capra; Renato Zambello; Nicola Cascavilla; Paolo de Fabritiis; Vanessa Innao; Francesca Bonello; Francesca Patriarca; Giulia Benevolo; Nicola Giuliani; Gabriele Aitoro; Tommasina Guglielmelli; Francesco Di Raimondo; Paolo Corradini; Pellegrino Musto; Roman Hájek; Pieter Sonneveld; Mario Boccadoro; Sara Bringhen

doi:10.1038/s41408-021-00464-w

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

Mattia D’Agostino, Alessandra Larocca, Massimo Offidani, Anna Marina Liberati, Gianluca Gaidano, Maria Teresa Petrucci, Daniele Derudas, Andrea Capra, Renato Zambello, Nicola Cascavilla, Paolo de Fabritiis, Vanessa Innao, Francesca Bonello, Francesca Patriarca, Giulia Benevolo, Nicola Giuliani, Gabriele Aitoro, Tommasina Guglielmelli, Francesco Di Raimondo, Paolo CorradiniPellegrino Musto, Roman Hájek, Pieter Sonneveld, Mario Boccadoro, Sara Bringhen

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Lingua originale	Inglese
Numero di articolo	73
Rivista	Blood Cancer Journal
Volume	11
Numero di pubblicazione	4
DOI	https://doi.org/10.1038/s41408-021-00464-w
Stato di pubblicazione	Pubblicato - apr 2021

Accesso al documento

10.1038/s41408-021-00464-w

Altri file e collegamenti

Link to publication in Scopus

Cita questo

D’Agostino, M., Larocca, A., Offidani, M., Liberati, A. M., Gaidano, G., Petrucci, M. T., Derudas, D., Capra, A., Zambello, R., Cascavilla, N., de Fabritiis, P., Innao, V., Bonello, F., Patriarca, F., Benevolo, G., Giuliani, N., Aitoro, G., Guglielmelli, T., Di Raimondo, F., ... Bringhen, S. (2021). Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 11(4), Articolo 73. https://doi.org/10.1038/s41408-021-00464-w

@article{2fda6020f9f14555b685cd9b31c66e88,

title = "Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score",

author = "Mattia D{\textquoteright}Agostino and Alessandra Larocca and Massimo Offidani and Liberati, {Anna Marina} and Gianluca Gaidano and Petrucci, {Maria Teresa} and Daniele Derudas and Andrea Capra and Renato Zambello and Nicola Cascavilla and {de Fabritiis}, Paolo and Vanessa Innao and Francesca Bonello and Francesca Patriarca and Giulia Benevolo and Nicola Giuliani and Gabriele Aitoro and Tommasina Guglielmelli and {Di Raimondo}, Francesco and Paolo Corradini and Pellegrino Musto and Roman H{\'a}jek and Pieter Sonneveld and Mario Boccadoro and Sara Bringhen",

note = "Funding Information: M.D. has received honoraria for lectures from Sanofi and GSK; has served on the advisory boards for GSK. A.L. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and GSK; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. M.O. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda; has served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda. A.M.L. has received personal fees from Incyte; has received research funding from Novartis, Janssen, AbbVie, Roche, Celgene, Amgen, Bristol-Myers Squibb, Takeda, Incyte, Pfizer, Beigene, Oncopeptides, Verastem, Karyopharm, Archigen, Biopharma, Debiopharm, Morphosys, Fibrogen, and Onconova. G.G. has served on the advisory boards for Janssen, AbbVie, and AstraZeneca; has served on the speaker{\textquoteright}s bureaus for Janssen and AbbVie. M.T.P. has received honoraria from and served on the advisory boards for Celgene, Janssen-Cilag, Amgen, Bristol-Myers Squibb, Takeda, Sanofi, and GSK. R.Z. has served on the advisory boards for Janssen and Celgene. F.P. has served on the advisory boards for Celgene and Janssen. G.B. has received honoraria from Novartis, Celgene Amgen, and Takeda. N.G. has received research grants from Celgene and Janssen Pharmaceutica; has received sponsorship for clinical studies from Janssen Pharmaceutica, Millennium Pharmaceuticals, and GSK; has served on the advisory boards for Celgene, Takeda, and Janssen Pharmaceutica; has received support for participating in meetings from Janssen Pharmaceutica, Celgene, and Bristol-Myers Squibb. F.D.R. has received honoraria from Celgene, Janssen, Amgen, and Takeda. P.C. has participated as a lecturer and/or has served on the advisory boards for AbbVie, ADC Therapeutics, Amgen, Celgene, Daiichi Sankyo, Gilead, Incyte, Janssen, Jazz Pharmaceuticals, Kite, Kyowa Kirin, Novartis, Roche, Sanofi, Servier, and Takeda. P.M. has received honoraria and/or served on the scientific advisory boards for Celgene, Janssen, Takeda, Bristol-Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and Glaxo-Smith-Kline. R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. P.S. has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, Seattle Genetics, Takeda, and Karyopharm. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. S.B. has received honoraria from Celgene, Amgen, Janssen, and Bristol-Myers Squibb; has served on the advisory boards for Celgene, Amgen, Janssen, and Karyopharm; has received consultancy fees from Janssen and Takeda. The remaining authors declare no competing interests.",

year = "2021",

month = apr,

doi = "10.1038/s41408-021-00464-w",

language = "English",

volume = "11",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "4",

}

D’Agostino, M, Larocca, A, Offidani, M, Liberati, AM, Gaidano, G, Petrucci, MT, Derudas, D, Capra, A, Zambello, R, Cascavilla, N, de Fabritiis, P, Innao, V, Bonello, F, Patriarca, F, Benevolo, G, Giuliani, N, Aitoro, G, Guglielmelli, T, Di Raimondo, F, Corradini, P, Musto, P, Hájek, R, Sonneveld, P, Boccadoro, M & Bringhen, S 2021, 'Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score', Blood Cancer Journal, vol. 11, n. 4, 73. https://doi.org/10.1038/s41408-021-00464-w

TY - JOUR

T1 - Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments

T2 - the role of age >80 in the IMWG frailty score

AU - D’Agostino, Mattia

AU - Larocca, Alessandra

AU - Offidani, Massimo

AU - Liberati, Anna Marina

AU - Gaidano, Gianluca

AU - Petrucci, Maria Teresa

AU - Derudas, Daniele

AU - Capra, Andrea

AU - Zambello, Renato

AU - Cascavilla, Nicola

AU - de Fabritiis, Paolo

AU - Innao, Vanessa

AU - Bonello, Francesca

AU - Patriarca, Francesca

AU - Benevolo, Giulia

AU - Giuliani, Nicola

AU - Aitoro, Gabriele

AU - Guglielmelli, Tommasina

AU - Di Raimondo, Francesco

AU - Corradini, Paolo

AU - Musto, Pellegrino

AU - Hájek, Roman

AU - Sonneveld, Pieter

AU - Boccadoro, Mario

AU - Bringhen, Sara

N1 - Funding Information: M.D. has received honoraria for lectures from Sanofi and GSK; has served on the advisory boards for GSK. A.L. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and GSK; has served on the advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda. M.O. has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda; has served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, GSK, Sanofi, and Takeda. A.M.L. has received personal fees from Incyte; has received research funding from Novartis, Janssen, AbbVie, Roche, Celgene, Amgen, Bristol-Myers Squibb, Takeda, Incyte, Pfizer, Beigene, Oncopeptides, Verastem, Karyopharm, Archigen, Biopharma, Debiopharm, Morphosys, Fibrogen, and Onconova. G.G. has served on the advisory boards for Janssen, AbbVie, and AstraZeneca; has served on the speaker’s bureaus for Janssen and AbbVie. M.T.P. has received honoraria from and served on the advisory boards for Celgene, Janssen-Cilag, Amgen, Bristol-Myers Squibb, Takeda, Sanofi, and GSK. R.Z. has served on the advisory boards for Janssen and Celgene. F.P. has served on the advisory boards for Celgene and Janssen. G.B. has received honoraria from Novartis, Celgene Amgen, and Takeda. N.G. has received research grants from Celgene and Janssen Pharmaceutica; has received sponsorship for clinical studies from Janssen Pharmaceutica, Millennium Pharmaceuticals, and GSK; has served on the advisory boards for Celgene, Takeda, and Janssen Pharmaceutica; has received support for participating in meetings from Janssen Pharmaceutica, Celgene, and Bristol-Myers Squibb. F.D.R. has received honoraria from Celgene, Janssen, Amgen, and Takeda. P.C. has participated as a lecturer and/or has served on the advisory boards for AbbVie, ADC Therapeutics, Amgen, Celgene, Daiichi Sankyo, Gilead, Incyte, Janssen, Jazz Pharmaceuticals, Kite, Kyowa Kirin, Novartis, Roche, Sanofi, Servier, and Takeda. P.M. has received honoraria and/or served on the scientific advisory boards for Celgene, Janssen, Takeda, Bristol-Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and Glaxo-Smith-Kline. R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. P.S. has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, Seattle Genetics, Takeda, and Karyopharm. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. S.B. has received honoraria from Celgene, Amgen, Janssen, and Bristol-Myers Squibb; has served on the advisory boards for Celgene, Amgen, Janssen, and Karyopharm; has received consultancy fees from Janssen and Takeda. The remaining authors declare no competing interests.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85104245323&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00464-w

DO - 10.1038/s41408-021-00464-w

M3 - Letter

SN - 2044-5385

VL - 11

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 4

M1 - 73

ER -